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Vestibular damage can induce locomotor abnormalities in both animals and humans.
Rodents with bilateral vestibular loss showed vestibular deficits syndrome such as
circling, opisthotonus as well as locomotor and exploratory hyperactivity. Previous studies
have investigated the changes in the dopamine system after vestibular loss, but the
results are inconsistent and inconclusive. Numerous evidences indicate that the orexin
system is implicated in central motor control. We hypothesized that orexin may be
potentially involved in vestibular loss-inducedmotor disorders. In this study, we examined
the effects of arsanilate- or 3,3′-iminodipropionitrile (IDPN)-induced vestibular lesion (AVL
or IVL) on the orexin-A (OXA) labeling in rat hypothalamus using immunohistochemistry.
The vestibular lesion-induced locomotor abnormalities were recorded and verified using a
histamine H4 receptor antagonist JNJ7777120 (20mg/kg, i.p.). The effects of the orexin
receptor type 1 antagonist SB334867 (16 µg, i.c.v.) on these behavior responses were
also investigated. At 72 h post-AVL and IVL, animals exhibited vestibular deficit syndrome
and locomotor hyperactivity in the home cages. These responses were significantly
alleviated by JNJ7777120 which also eliminated AVL-induced increases in exploratory
behavior in an open field. The numbers of OXA-labeled neurons in the hypothalamus
were significantly increased in the AVL animals at 72 h post-AVL and in the IVL animals
at 24, 48, and 72 h post-IVL. SB334867 significantly attenuated the vestibular deficit
syndrome and locomotor hyperactivity at 72 h post-AVL and IVL. It also decreased
exploratory behavior in the AVL animals. These results suggested that the alteration of
OXA expression might contribute to locomotor abnormalities after acute vestibular lesion.
The orexin receptors might be the potential therapeutic targets for vestibular disorders.
Keywords: vestibular lesion, orexin, hypothalamus, locomotor activity, exploratory behavior
INTRODUCTION
Peripheral vestibular system located in the inner ear conveys information about the body motion
and the gravity (Wiest, 2015). Previous studies confirmed that bilateral vestibular loss produces
remarkable behavior abnormalities (circling, retropulsion, opisthotonus, and moderate ataxia) and
hyperactivity in the animals receivingmechanical or chemical labyrinthectomy and in themice with
genetic deficiency in the vestibular endorgans (Llorens and Rodríguez-Farré, 1997; Kaiser et al.,
2001; Schirmer et al., 2007a; Goddard et al., 2008; Vignaux et al., 2012). These behavior responses
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occur spontaneously or in response to stress such as placing the
animal in a new environment (Lindemann et al., 2001). Animals
with the deficits in the inner ear also exhibited marked vestibular
dysfunction during the air-righting reflex test and the tail-
hanging test (Hunt et al., 1987; Ossenkopp et al., 1990). Recently,
it was reported that the vestibular deficits induced by systemic
administration of 3,3′-iminodipropionitrile (IDPN) or by intra-
tympanic injections of kainate were improved by the histamine
H4 receptor (H4R) antagonists which exhibited pronounced
inhibitory effects on the vestibular neuron activity (Desmadryl
et al., 2012; Wersinger et al., 2013). This indicates that the
vestibular damage is responsible for the behavior abnormalities
such as circling, opisthotonus, and locomotor hyperactivity.
Although there was evidence that vestibular loss may
potentially influence the activity of the forebrain dopamine
systems, the results that were derived from different types
of vestibular deficits were inconsistent (Löscher, 2010).
Pharmacological studies showed that the dopamine D2 receptor
antagonist eliminated the hyperactivity and circling behaviors
in the ci2 mutant rats with vestibular deficits but not in animals
receiving surgical vestibular deafferentation (Schirmer et al.,
2007b; Stiles et al., 2012). Histochemical examination of the
striatum and the substantia nigra pars compacta failed to disclose
any abnormalities in the density of the dopaminergic neurons
in streptomycin-treated LEW/Ztm rats, whereas a significant
asymmetry in the density of the dopaminergic neurons was
determined in the ventral tegmental area in the ci2 mutant rats
(Schirmer et al., 2007a). These results strongly suggested that
the vestibular loss-related motor disorders cannot be solely
explained by the functional alterations in the dopaminergic
system (Palomero-Gallagher et al., 2008, 2010).
Recently, the orexin (hypocretin) neuropeptide producing
neurons which are located in the hypothalamus including
the lateral hypothalamic area (LHA), the perifornical area
(PFA), the dorsomedial hypothalamus (DMH), and the posterior
hypothalamus were found to play critical roles in regulating sleep
and wakefulness (Sinton, 2011). Numerous evidences indicate
that the orexin system also plays key roles in central motor
control (Hu et al., 2015). Orexin-A (OXA) that was administrated
into the hypothalamic paraventricular nucleus dose-dependently
increased the spontaneous physical activity in rats, while the
orexin receptor type 1 (OX1R) antagonist SB334867 significantly
attenuated such effects (Kiwaki et al., 2004). The increases in the
locomotor activity were also observed after the injection of the
orexin peptides into the rostral lateral hypothalamic area, the
nucleus accumbens, the locus coeruleus, the dorsal raphe nucleus,
the tuberomammillary nucleus, or the substantia nigra (Zink
et al., 2014). Moreover, the elevated orexin receptor expression
levels were found to be associated with higher activity in the
obesity-resistant rats than in the obese rats (Teske et al., 2006,
2013). OXA dose-dependently potentiated the contraversive
pivoting that was induced by the activation of the dopamine
D1 and D2 receptor in the nucleus accumbens shell, whereas
SB334867 did not affect the pivoting (Kotani et al., 2008).
In addition, anatomical studies have demonstrated that the
vestibular nucleus complex has reciprocal connections with the
LHA (Matsuyama et al., 1996; Horowitz et al., 2005; Ciriello
and Caverson, 2014). The brainstem regions which receive the
direct innervations from the vestibular nucleus such as the dorsal
raphe nucleus, the lateral parabrachial nucleus and the locus
coeruleus also contain considerable efferent neurons that directly
project to the LHA region (Yoshida et al., 2006). Based on these
observations, we hypothesized that the orexin system may be
potentially involved in the motor disorders that are induced by
vestibular dysfunction.
The present study observed the alteration of OXA labeling
in the hypothalamus and tested the behavior abnormalities
that were induced by two different approaches of chemical
vestibular lesion (VL) in rats. The chemical vestibular lesions
were induced by the systemic injection of IDPN or the intra-
tympanic injection of sodium arsanilate. These chemicals can
cause lesions in the vestibular hair cells and sensory epithelia
as previously described (Desmadryl et al., 2012; Martin et al.,
2015). Vestibular deficit syndrome (circling, retropulsion and
head bobbing as well as contact inhibition of the righting
reflex and abnormalities in tail-hanging reflex and air-righting
reflex), spontaneous locomotor activity in the home cages
and exploratory behavior in a new environment (open field)
were observed after the vestibular lesions. The VL-related
behavior responses were verified via the application of a selective
non-imidazole H4R antagonist JNJ7777120 which has been
found to be a pronounced inhibitor on the activity of the
vestibular neurons at a dose of 20 mg/kg body weight in rats
(Desmadryl et al., 2012). The efficacy of the OX1R inhibitor
SB334867 on the VL-induced behavior abnormalities was also
investigated.
MATERIALS AND METHODS
Animals and Ethics
Adult male Sprague–Dawley rats weighing 250–300 g were
purchased from the Laboratory Animal Center in Shanghai. The
animals were individually housed under a 12 h light: 12 h dark
cycle (temperature: 22 ± 2◦C and lighting: 8:00–20:00) with
free access to food and water. All animals were acclimated to
the lab environment with the temperature maintained at 22◦C
for 2 weeks before the initiation of the experiment. All animal
protocols and procedures complied with the Guide for the Care
and Use of Laboratory Animals (National Research Council
(US) Institute for Laboratory Animal Research, 1996) and were
approved by the Ethics Committee for Animal Experimentation
of the Second Military Medical University (Shanghai, PR China).
Efforts were made to minimize the number of animals used and
their suffering in each experiment. The implantation surgeries
were performed under sodium pentobarbital (40mg/kg, i.p.)
anesthesia. The animals were allowed a 7-day recovery after
the surgery. The intra-tympanic injections were conducted
under volatile anesthesia (2% isoflurane) in oxygen (flow
rate of 2 L/min). All animals received antibiotics penicillin
(400000U/kg, i.p.) and analgesics ibuprofen (30mg/kg, in the
drinking water) once a day for 3 days after the implantation
surgery and the intra-tympanic injection.
Vestibular Lesion Procedures
Two different models of chemical vestibular lesion were
produced in this study. In the arsanilate-induced VL (AVL)
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model, vestibular deficits were elicited by the intra-tympanic
injection of a single dose (50–100 µl) of sodium arsanilate
(30% w/v) bilaterally in rats. The sham control (SHAM) animals
received the intra-tympanic injections of saline (0.9% w/v)
following the same procedures. In the IDPN-induced VL (IVL)
model, vestibular deficits were produced by the intraperitoneal
(i.p.) injection of a single dose of IDPN (900mg/kg body
weight) in rats. The saline control (SAL) animals received
the i.p. injection of 1ml saline solution (0.9% w/v) instead.
All these operations were performed between 4:00 and 6:00
p.m. All animals were allowed a 2-h recovery before further
experiments.
Experimental Design and Grouping
Experiment 1
In this experiment, OXA labeling in the hypothalamus was
observed in the VL animals. Seventy-two rats were used and
randomly divided into the following groups: the AVL or the IVL
group and the corresponding SHAM or SAL group (n = 18
in each group). Animals in each group were evenly assigned
into three subgroups after the recovery from the VL or control
treatment (n = 6 in each subgroup). They received the behavior
tests at 24, 48, or 72 h post-VL, respectively, and were killed for
OXA immunostaining immediately after the tests.
Experiment 2
The effects of the H4R antagonist JNJ7777120 on the VL-
induced behavioral responses were observed in this part. Sixty-
four animals were used and randomly divided into eight groups:
two AVL or two IVL groups and corresponding two SHAM or
two SAL groups. Animals in the two groups in pairs received
an i.p. injection of either 1ml JNJ7777120 (JNJ, 20mg/kg body
weight) or 1ml vehicle (Veh) solution (dimethyl sulfoxide,
DMSO) at 72 h after the VL or control treatment (n = 8 in each
group). All rats received behavioral test 30min after the drug
injections.
Experiment 3
The effects of the intracerebroventricular (i.c.v.) injection of the
OX1R antagonist SB334867 (SB) on the VL-induced behavior
responses were examined. The animal groupings and the
experimental procedures in this experiment were the same as
the Experiment 2, instead that the animals were injected with
4 µl SB334867 (16 µg) or 4 µl Veh (i.c.v.) 30min before the
behavior tests according to the pilot studies. At the end, 6ml of
2% pontamine sky blue solution was administrated to mark the
injection sites after the termination of the animals with overdose
pentobarbitone (100mg/kg, i.p.). Only those animals with the
blue staining in the lateral and fourth ventricles were included
in the further analyses.
Surgery Procedures
Intracerebroventricular Injection
A 23-gauge stainless steel guide cannulae (RWD Life Science,
Shenzhen, China) was implanted into the right lateral ventricle
(0.9mm caudal to the Bregma, 1.5mm lateral to the midline, and
3.5mm below the dura). During drug administration, the guide
cannulae were fitted with a 30-gauge stainless steel injection
needle that extended 0.5mm beyond the tip of the guide
cannulae. The drug solution was injected by pressure over a
period of 5 s.
Activity Sensor Implantation
The implantation surgery was carried out according to the
manufacturer’s instructions (DSI, St. Paul, USA). An activity
sensor (TA10TA-F40) was implanted intra-abdominally after
midline laparotomy and then the abdominal muscles and skins
were sutured under anesthesia.
Behavior Test
Vestibular Deficit Test
The vestibular deficit syndrome was evaluated by observing the
behavior responses including the behavior abnormalities and
the vestibular reflex dysfunctions described previously (Vignaux
et al., 2012). During the behavior abnormality test, rats were
placed for 1 min on a table top, and the experimenter rated
the animals from 0 to 4 for circling, retropulsion, and abnormal
head movements. Circling was defined as stereotyped circling
movement. Retropulsion consisted of backward displacement
of the animal. Head bobbing consisted of intermittent extreme
backward extension of the neck. During vestibular reflex test,
tail-hanging reflex, contact inhibition of the righting reflex, and
the air-righting reflex test were examined. For the tail-hanging
reflex test, animals were lifted by the tail. Normal rats exhibit
a “landing” response consisting of forelimb extension, while
rats with impaired vestibular function bent ventrally, sometimes
“crawling” up toward their tails, and thus tending to occipital
landing. For the contact inhibition of the righting reflex test, rats
were placed supine on a horizontal surface, and a metal bar grid
was lightly placed in contact with the soles of the animals’ feet.
Healthy rats quickly right themselves, whereas the vestibular-
deficient rats lie on their back, with their feet up, and “walk”
with respect to the ventral surface. For the air-righting reflex test,
the animals were held supine and dropped from a height of 40
cm onto a foam cushion. A vestibular deficit score was obtained
by adding up the scores for all of the behavior responses and
expressed as a percentage of the maximal score of 24 (Hunt et al.,
1987; Ossenkopp et al., 1990; Vignaux et al., 2012).
Open Field Test
The exploratory behavior was measured using an open field
test system (RD1112-IFO-R-4, Mobiledatum, Shanghai, China)
immediately after the vestibular deficit test. The apparatus
consisted of a dark 40 × 40 × 45 cm rectangular chamber with
the floor marked with a 16 × 16 grid. The test was conducted
in a soundproof room. An animal was placed in the center
of the chamber and left undisturbed for 5 min. The behaviors
and locomotion tracking of the animal were recorded by an
infrared digital video camera. The total distance traveled (cm),
body center-point moving duration (s), highly mobile duration
(s), and immobile (inactivity) duration (s) were analyzed using
a commercially available software (EthoVision XT 8.5, Noldus,
Netherlands).
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Home Cage Locomotor Activity Test
Horizontal linear motion in the home cages was measured
immediately after the open field test. The DSI activity sensor was
activated with a magnet 30 min after the animals were placed
back to their home cages. Spontaneous locomotor activity in the
home cages were monitored continuously for 2 h without any
external disturbances. The numbers of activity were recorded
and analyzed using DSI software (Dataquest A.R.T system, DSI,
USA).
OXA Immunohistochemistry
Animals were anesthetized with an overdose of sodium
pentobarbital (100mg/kg, i.p.) and then perfused transcardially
with 100ml chilled saline, followed by the perfusion with
500ml 0.1 mol/l phosphate buffer (PB, pH 7.4) containing 4%
paraformaldehyde. The brains were removed, post-fixed with 4%
paraformaldehyde at 4◦C for 1 h; a brain block including the
hypothalamus was made and placed in 0.1mol/l PB containing
30% sucrose overnight at 4◦C. Then the blocks were cut
into 20 µm-thick sections. One out of every 3 consecutive
sections (2.2–3.4mm caudal to the Bregma) where the OXA-
labeled (OXA-LI) neurons were mainly located was selected for
immunostaining.
The tissue sections were washed in 0.01M phosphate-buffered
solution (PBS, pH 7.4) and incubated in a mouse anti-OXA IgG
(R&D Systems; 1:500) for 24 h at 4◦C. After being washed in the
PBS, the sections were incubated in a biotinylated horse anti-
mouse IgG (Vector Laboratories; 1:200) for 4 h. OXA labeling
was visualized using a ABC immunoperoxidase method. In
brief, the samples were exposed to 1:100 streptavidin–horseradish
peroxidase (HRP, Vector Laboratories, Burlingame, CA) for 4 h
at 4◦C. After being washed in PBS again, the sections were
incubated in 0.05M Tris-buffer (pH 7.6) containing 0.1% 3,3′-
diaminobenzidine tetrahydrochloride (DAB; Sigma, St. Louis,
MO) and 0.003% H2O2. Some control sections were processed
without the primary antibody to rule out the non-specific
immunostaining in these sections. Sections from comparable
rostrocaudal levels of the hypothalamus (20 sections per animal)
in each rat were chosen for cell counting. The number of the
OXA-LI neurons was counted under a light microscope by a rater
unaware of the experimental conditions. The photographs were
taken with a digital camera.
Drugs Preparation
Sodium arsanilate (Sigma-Aldrich, St. Louis, USA) and IDPN
(Fisher Scientific, Illkirch, France) were dissolved in 0.9%
saline solution. JNJ7777120 (SelleckChem, Houston, USA) was
prepared in 100% DMSO. SB-334867 (MedChem Express,
Princeton, USA) was dissolved in the aCSF (in mM: 133.3 NaCl,
3.4 KCl, 1.3 CaCl2, 1.2 MgCl2, 0.6 NaH2PO4, 32.0 NaHCO3, and
3.4 glucose, with pH adjusted to 7.4).
Data Analysis
All statistical analyses were conducted using the SPSS v13.0
program. In Experiment 1, two-way ANOVA analysis was
performed to examine the differences among the AVL, IVL or
control groups. Fisher’s LSD post-hoc test was used when a
significant main effect or an interaction effect was obtained. In
Experiment 2 and 3, one-way ANOVA analysis was performed to
analyze the differences among groups followed by the Bonferroni
post-hoc test when it is applicable. Data are expressed as the mean
± SD. The level of significance was set at 0.05.
RESULTS
Behavior Responses in the AVL and IVL
Animals
Table 1 shows the behavior responses after the AVL and IVL
treatment in rats. Vestibular deficit analysis revealed significant
effects of AVL [F(1, 35) = 4748.80, P < 0.001] and time
[F(2, 35) = 45.49, P < 0.001] and an AVL × time interaction
[F(2, 35) = 45.49, P < 0.001]. Vestibular deficit scores were
significantly increased at all of the time points in the AVL groups
compared with the corresponding SHAM groups (P < 0.001).
Significant IVL [F(1, 35) = 4088.92, P < 0.001] and time
[F(2, 35) = 1067.50, P < 0.001] effects and an IVL × time
interaction [F(2, 35) = 1067.50, P < 0.001] were also observed.
The IVL animals exhibited the vestibular deficit syndrome at 48
and 72 h after the injection of IDPN compared with the SAL
controls (P < 0.001). The vestibular deficit syndrome was fully
induced at 72 h in the AVL and IVL groups (Table 1). Neither
the SHAM nor the SAL control animals showed any signs of the
vestibular deficit symptom.
Two-way ANOVA analysis revealed significant effects of AVL
[F(1, 35) = 54.593, P < 0.001] and time [F(2, 35) = 68.417,
P < 0.001] and an AVL × time interaction [F(2, 35) = 30.242,
P < 0.001] on locomotor activity in the home cages. Post-
hoc analysis revealed that arsanilate significantly increased the
number of activity at 48 h (P < 0.001) and 72 h (P < 0.001) in the
AVL groups compared with the corresponding SHAM groups.
There were also significant IVL [F(1, 35) = 30.242, P= 0.012] and
time [F(2, 35) = 6.130, P = 0.006] effects on locomotor activity
in the home cages. IDPN significantly increased the number of
activity in the home cages at 72 h in the IVL group compared
with the SAL group (P < 0.001, Table 1).
During the open field test, the AVL animals but not the SHAM
controls showed increased exploratory behavior. Significant AVL
[F(1, 35) = 7.264, P< 0.001] and time [F(2, 35) = 17.773, P< 0.05]
effects and an AVL × time interaction [F(2, 35) = 15.989, P <
0.001] on total distance traveled were observed. Total distance
traveled was initially decreased at 24 h (P < 0.001), recovered
back to the control level at 48 h and was significantly increased
at 72 h (P < 0.001) in the AVL groups compared with the
SHAM groups. Meanwhile, AVL [F(1, 35) = 7.826, P < 0.01],
time [F(2, 35) = 66.764, P < 0.001] and AVL × time interaction
[F(2, 35) = 57.040, P < 0.0001] had significant effects on center
point moving duration which was decreased at 24 h (P < 0.001)
and increased at 48 h (P < 0.05) and 72 h (P < 0.001) in the
AVL groups. A significant AVL effect was also observed in highly
mobile duration [F(1, 35) = 7.662, P < 0.01] and immobile
duration [F(1, 35) = 29.322, P < 0.001]. Highly mobile duration
was increased at 48 h (P < 0.01) and 72 h (P < 0.001) after the
injection of arsanilate, whereas immobile duration was decreased
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TABLE 1 | Effects of vestibular lesion (VL) on the vestibular deficit syndrome, home cage locomotor activity and exploratory behavior.
Vestibular deficit
score (%)
Home cage locomotor
activity (counts/min)
Exploratory behaviors
Total distance
traveled (cm)
Center-point
moving (s)
Highly mobile
duration (s)
Immobile
duration (s)
24 H POST–VL
AVL 63.19± 6.67*** 8.45±0.96 40.51± 9.90*** 64.20±11.93*** 1.63±0.79 143.80± 21.27
SHAM 0.00± 0.00 9.44±0.91 109.67± 14.76 105.33±6.14 1.13±0.78 124.43± 9.39
IVL 4.16± 3.72 9.51±3.01 63.84± 7.86 # # 62.86±13.08## 2.13±1.47 150.03± 21.81##
SAL 0.00± 0.00 9.88±2.43 144.45± 13.76 119.23±3.28 0.86±0.61 114.56± 7.82
48 H POST–VL
AVL 84.72± 4.30*** 14.78±2.01*** 176.56± 17.03 133.70±15.65* 9.70±3.97** 84.90± 21.44**
SHAM 0.00± 0.00 9.28±1.92 121.15± 6.53 111.00±6.79 1.77±0.63 116.96± 8.58
IVL 52.77± 3.40### 11.81±2.92 100.41± 17.61## 104.03±13.70 3.90±1.63 127.03± 12.04
SAL 0.00± 0.00 9.18±3.09 124.02± 18.37 113.20±9.06 1.46±0.78 126.16± 15.05
72 H POST–VL
AVL 87.50± 2.64*** 22.81±2.61*** 307.74± 34.30*** 162.70±9.80*** 16.66±2.16*** 37.93± 17.34***
SHAM 0.00± 0.00 10.83±1.99 116.47± 26.49 112.00±13.58 1.15±0.37 121.43± 17.33
IVL 91.67± 2.63### 16.55±2.02### 75.51± 19.78## 104.43±23.38 2.68±1.35# 120.90± 15.06
SAL 0.00± 0.00 10.87±2.84 125.24± 23.13 109.73±14.22 1.10±0.62 116.16± 8.98
AVL, Arsanilate-induced Vestibular Lesion; SHAM, Sham control; IVL, IDPN-Induced Vestibular Lesion; SAL, Saline control.
*P < 0.05, **P < 0.01, and ***P < 0.001 compared with corresponding SHAM group.
#P < 0.05, ##P < 0.01, and ###P < 0.001 compared with corresponding SAL group.
at these time points (P < 0.01 and P < 0.001) in the AVL groups
compared with the SHAM groups.
Additionally, there was a significant IVL [F(1, 35) = 33.624,
P < 0.001] effect and an IVL× time interaction [F(2, 35) = 4.204,
P < 0.05] on total distance traveled which was significantly
decreased in the IVL animals at all of the time points after the
injection of IDPN compared with the SAL controls (P < 0.01).
The IVL treatment also had significant effects on center-point
moving [F(2, 35) = 14.170, P < 0.001] as well as highly mobile
duration [F(2, 35) = 8.018, P < 0.01] and immobile duration
[F(2, 35) = 9.865, P < 0.005]. Compared with the SAL controls,
the IVL animals showed a decrease in center-point moving
duration and an increase in immobile duration at 24 h (P < 0.01)
as well as an increase in highly mobile duration at 72 h (P < 0.05,
Table 1). There were no significant effects of surgery or time on
all of the variables in the SHAM or SAL groups during the open
field test.
Effects of AVL and IVLon OXA-Labeling in
the Hypothalamus
Table 2 shows the numbers of the OXA-LI neurons in different
regions of the rat hypothalamus (−2.2 ∼ −2.6, −2.6 ∼ −3.0,
and −3.0 ∼ −3.4mm relative to the Bregma) after the AVL
and IVL treatment. The densest concentration of the OXA-
LI neurons was observed within Bregma −2.6 ∼ –3.0mm of
the bilateral LHA, PFA, and DMH (Figure 1). The positive
labeling was not observed in any control sections that were
processed without the primary antibody. Two-way ANOVA
analysis revealed significant AVL [F(1, 35) = 9.264, P < 0.01]
and time [F(2, 35) = 6.371, P < 0.01] effects and an AVL ×
time interaction [F(2, 35) = 6.763, P < 0.01], and a significant
TABLE 2 | Effects of vestibular lesion (VL) on the number of
orexin-A-labeled neurons in the hypothalamus.
Bregma −2.2 ∼
−2.6mm
Bregma −2.6 ∼
−3.0mm
Bregma −3.0
∼ −3.4mm
24 H POST–VL
AVL 45.00± 14.90 474.25± 20.79 250.00± 19.44
SHAM 51.00± 9.93 465.25± 30.12 213.00± 34.37
IVL 43.25± 9.11 609.00± 46.65## 380.50± 23.02
SAL 47.25± 7.13 459.75± 43.27 228.25± 31.85
48 H POST–VL
AVL 35.50± 7.23 514.25± 28.86 298.50± 24.07
SHAM 42.37± 6.24 491.00± 27.60 247.50± 38.38
IVL 75.75± 16.74# 642.50± 23.29## 336.83± 26.22#
SAL 47.75± 12.09 455.75± 28.73 275.00± 33.64
72 H POST–VL
AVL 69.37± 9.69* 579.50± 29.16** 343.00± 40.16**
SHAM 43.00± 8.29 467.25± 29.65 235.00± 32.54
IVL 80.25± 14.08## 603.50± 38.21## 336.25± 30.27##
SAL 37.00± 10.74 497.73± 31.87 253.50± 27.01
AVL, Arsanilate-induced Vestibular Lesion; SHAM, Sham control; IVL, IDPN-Induced
Vestibular Lesion; SAL, Saline Control.
*P < 0.05, **P < 0.01 compared with corresponding SHAM group;
#P < 0.05, ##P < 0.01 compared with corresponding SAL group.
IVL [F(2, 35) = 114.026, P < 0.001] effect and an IVL ×
time interaction [F(2, 35) = 3.478, P < 0.05] on the number
of the OXA-LI neurons within this region. Post-hoc analysis
showed that the number of the OXA-LI neurons was significantly
increased at 72 h in the AVL group compared with the SHAM
group (P < 0.01; Figure 1C). Meanwhile, the IVL treatment
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FIGURE 1 | Representative photomicrographs showing orexin-A-labeled (OXA-LI) neurons in rat hypothalamus (Bregma −2.6 ∼ −3.0mm) in the
arsanilate-induced vestibular lesion (AVL), the sham control (SHAM), the IDPN-induced vestibular lesion (IVL), and the saline control (SAL) groups at
24h (A1–A4), 48 h (B1–B4), or 72h (C1–C4) after recovery from vestibular lesion or control treatment. LHA, lateral hypothalamic area; PFA, perifornical area;
DMH, dorsomedial hypothalamus. Bar = 400 µm.
increased the number of the OXA-LI neurons at all of the time
points compared with the SAL control treatment (P < 0.01;
Figures 1A,C). No significant differences were observed at 24
and 48 h between the AVL and SHAM groups (Figures 1A,B).
Two-way ANOVA analysis also found a significant AVL
[F(1, 35) = 21.296, P < 0.001] effect and an AVL ×
time interaction [F(2, 35) = 12.179, P < 0.001]; significant
IVL [F(2, 35) = 48.506, P < 0.001] and time [F(1, 35) =
10.789, P < 0.001] effects and an IVL × time interaction
[F(2, 35) = 14.019, P < 0.001] on the number of the OXA-
LI neurons within Bregma −2.2 ∼ −2.6mm. Significant AVL
[F(2, 35) = 20.330, P < 0.01] and time [F(1, 35) = 7.709, P < 0.01]
effects and a significant IVL [F(2, 35) = 25.141, P < 0.001] effect
on the number of OXA-LI neurons were also observed within
Bregma −3.0 ∼ −3.4mm. The numbers of the OXA-LI neurons
in these regions were significantly increased at 72 h in the AVL
group (P < 0.05, Figure 1C) and at 48 h (P < 0.05, Figure 1B)
and 72 h (P < 0.01, Figure 1C) in the IVL groups compared with
the corresponding control groups.
Effects of JNJ7777120 on the Behavior
Responses in the AVL and IVL Animals
Table 3 shows the effects of the i.p. injection of the H4R inhibitor
JNJ7777120 on the behavior responses at 72 h after the AVL
and IVL treatment. Compared with the corresponding SHAM-
Veh and SAL-Veh controls, the AVL-Veh and IVL-Veh animals
exhibited the vestibular deficit syndrome and hyperactivity in the
home cages (P < 0.001 or P < 0.01). Vestibular deficit score
was significantly decreased after JNJ7777120 administration in
the AVL and IVL groups but was still higher than in the SHAM-
Veh or SAL-Veh groups (P < 0.001). JNJ7777120 also inhibited
hyperactivity in the home cages in the AVL and IVL groups
compared with corresponding Veh groups (P < 0.001, Table 3).
During the open field test, the AVL-Veh treatment
significantly increased total distance traveled (P < 0.001),
center-point movement duration (P < 0.05), and highly
mobile duration (P < 0.001) and decreased immobile duration
(P < 0.001), whereas the IVL-Veh treatment significantly
increased highly mobile duration (P < 0.05) and deceased total
distance traveled (P < 0.05) compared with the corresponding
SHAM-Veh and SAL-Veh treatments (Table 3). JNJ7777120
significantly reduced total distance traveled, center-point moving
duration and highly mobile duration and increased immobile
duration in the AVL animals compared to the vehicle controls
(P < 0.001). Total distance traveled (P < 0.01) and center-point
moving duration (P < 0.05) were significantly decreased, while
immobile duration was significantly increased (P < 0.001) in
AVL-JNJ group compared with SHAM-Veh group. JNJ-7777120
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TABLE 3 | Effects of the histamine H4 receptor antagonist JNJ7777120 on the vestibular deficit syndrome, home cage locomotor activity and exploratory
behavior at 72 h post-vestibular lesion (VL).
Vestibular deficit
score (%)
Home cage locomotor
activity (counts/min)
Exploratory behavior
Total distance
traveled (cm)
Center-point
moving (s)
Highly mobile
duration (s)
Immobile
duration (s)
AVL EXPERIMENT
AVL-Veh 86.81± 4.43*** 23.77± 4.71*** 361.57±35.00*** 138.26±29.14* 13.80±2.64*** 59.46± 35.86***
AVL-JNJ 63.19± 5.63*** # ## 13.25± 2.63### 53.44±36.57** # ## 62.09±36.30* ### 1.70±1.01### 160.45± 19.18*** # ##
SHAM-Veh 0.00± 0.00 10.67± 2.22 109.84±10.48 104.54±12.48 1.80±1.50 125.28± 6.26
SHAM-JNJ 0.00± 0.00 9.75± 2.63 99.12±12.37 93.85±15.32 0.56±0.35 131.25± 4.67
IVL EXPERIMENT
IVL-Veh 83.33± 5.55*** 18.09± 2.06** 85.19±18.29* 123.83±22.45 3.86±1.60* 123.23± 21.83
IVL-JNJ 56.94± 7.71*** # ## 7.42± 1.53### 50.01±14.02***# 68.52±28.40** # # 1.13±1.03# 153.86± 20.10**#
SAL-Veh 0.00± 0.00 10.52± 3.72 115.15±25.02 103.75±13.24 0.47±0.28 117.68± 16.40
SAL-JNJ 0.00± 0.00 8.57± 1.99 97.43±15.31 107.20±11.26 0.44±0.32 122.86± 12.25
AVL, Arsanilate-induced Vestibular Lesion; SHAM, Sham control; IVL, IDPN-Induced Vestibular Lesion; SAL, Saline control Veh, vehicle solution; JNJ, JNJ7777120.
*P < 0.05, **P < 0.01, and ***P < 0.001 compared with corresponding SHAM-Veh or SAL-Veh group.
#P < 0.05, ##P < 0.01, and ###P < 0.001 compared with corresponding AVL-Veh or IVL-Veh group.
also significantly reduced total distance traveled (P < 0.05),
center-point movement duration (P <0.01) and highly mobile
duration (P < 0.05), and significantly increased immobile
duration (P < 0.05) in the IVL animals compared to the vehicle
controls. JNJ7777120 also significantly decreased total distance
traveled (P < 0.001) and center-point movement duration
(P < 0.01) and increased immobile duration (P < 0.01) in the
IVL-JNJ group compared with the SAL-Veh group. No changes
in any of the open field variables were observed after the i.p.
injection of JNJ7777120 in the SHAM or SAL control animals
(Table 3).
Effects of SB334867 on Behavior
Responses in the AVL and IVL Animals
In this experiment, vestibular deficit syndrome and hyperactivity
in the home cages were successfully induced in the AVL-Veh
and IVL-Veh animals compared with the corresponding SHAM-
Veh and SAL-Veh controls (P < 0.001, Figures 2, 3). In the
AVL-SB and IVL-SB groups, the i.c.v injection of the OX1R
antagonist SB334867 significantly reduced vestibular deficit
scores compared with the corresponding Veh groups (P < 0.001)
and the vestibular deficit scores were still higher than in the
SHAM-Veh and SAL-Veh groups (P < 0.001, Figures 2A,B).
SB334867 also attenuated the hyperactivity induced by the AVL
and IVL in the home cages (P < 0.001 and P < 0.05) compared
with the vehicle controls., The amounts of the locomotor activity
were still higher in the AVL-SB and IVL-SB groups than in
the SHAM-Veh and SAL-Veh groups (P < 0.01, Figures 3A,B).
In addition, SB334867 also reduced the locomotor activity in
the home cages in the SHAM and SAL animals compared with
corresponding Veh controls (P < 0.05, Figures 3A,B).
During the open field test, AVL-Veh animals showed
significant increases in total distance traveled (P < 0.001,
Figure 4A), center-point moving duration (P < 0.001,
Figure 4C) and highly mobile duration (P < 0.001, Figure 4E)
and a decrease in immobile duration (P < 0.001, Figure 4G)
compared with the SHAM-Veh controls. The IVL-Veh animals
exhibited a significant increase in highly mobile duration
(P < 0.01, Figure 4F) and a decrease in total distance traveled
(P < 0.01, Figure 4B) compared with the SAL-Veh controls.
SB334867 significantly reduced total distance traveled (P <
0.01, Figure 4A), center-point moving duration (P < 0.01,
Figure 4C) and highly mobile duration (P < 0.05, Figure 4E),
and increased immobile duration (P < 0.05, Figure 4G) in
the AVL-SB animals compared with AVL-Veh controls. Total
distance traveled (P < 0.05, Figure 4A) and highly mobile
duration (P < 0.01, Figure 4E) were increased and immobile
duration was decreased (P < 0.01, Figure 4G) in the AVL-SB
group compared with the SHAM-Veh group. In the IVL animals,
SB334867 reduced highly mobile duration compared to the
vehicle (P < 0.05, Figure 4F). SB334867 also decreased total
distance traveled (P < 0.01, Figure 4B) and center-point moving
duration (P < 0.05, Figure 4D) and increased immobile duration
(P < 0.05, Figure 4H) compared with SAL-Veh controls. In
the SHAM and SAL animals, SB334867 reduced total distance
traveled (P < 0.01, Figures 4A,B) and center-point moving
duration (P < 0.05, Figures 4C,D) and increased immobile
duration (P < 0.01, Figures 4G,H) but did not affect highly
mobile duration (P > 0.05, Figures 4E,F) compared with
corresponding Veh controls.
DISCUSSION
In the present study, arsanilate and IDPN successfully elicited the
vestibular deficit syndrome and hyperactivity in the home cages
in rats. These results were consistent with previous observations
which showed that both arsanilate and IDPN can damage the
vestibular endorgans in rodents (Boadas-Vaello et al., 2005;
Vignaux et al., 2012). Nevertheless, the exploratory behavior in
an open field was increased by arsanilate but decreased by IDPN.
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FIGURE 2 | Effects of the orexin receptor type 1 (OX1R) antagonist SB334867 on the vestibular deficit syndrome after vestibular lesions induced by
arsanilate (A) and IDPN (B) in rats. AVL, arsanilate-induced vestibular lesion; SHAM, sham control; IVL, IDPN-induced vestibular lesion; SAL, saline control; Veh,
vehicle solution; SB, SB334867. Data are represented as mean ± SEM. ***P < 0.001 compared with SHAM or SAL, vehicle control group; ###P < 0.001
compared with AVL or IVL vehicle control group.
FIGURE 3 | Effects of the orexin receptor type 1 (OX1R) antagonist SB334867 on locomotor activity in the home cages after vestibular lesions induced
by arsanilate (A) and IDPN (B) in rats. AVL, arsanilate-induced vestibular lesion; SHAM, sham control; IVL, IDPN-induced vestibular lesion; SAL, saline control; Veh,
vehicle solution; SB, SB334867. Data are represented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 compared with SHAM or SAL, vehicle control group;
#P < 0.05, ###P < 0.001 compared with AVL or IVL vehicle control group.
Such discrepancy might possibly be due to the differences in the
toxicity of these two chemicals. For example, the intra-tympanic
injection of arsanilate causes extensive damages in the vestibular
epithelia while the systemic application of IDPN induces an
inhomogeneous degeneration (Llorens and Demômes, 1996;
Boadas-Vaello et al., 2005; Vignaux et al., 2012; Martin et al.,
2015). IDPN can also induce some neuropathological effects
such as axonal swellings and neurofilamentous accumulation
in the central nervous system and cause reactive gliosis in the
retina and olfactory bulbs and the reversible opacification in the
cornea (Balbuena and Llorens, 2001; Boadas-Vaello et al., 2005;
Khan et al., 2009). In addition, we also showed that the H4R
antagonist significantly alleviated the vestibular deficit syndrome
and completely abolished hyperactivity in the home cages in
the arsanilate- and IDPN-treated animals. Blockade of the H4R
also significantly reduced exploratory behavior in an open field
in these animals. Although the H4R is expressed in the cortex,
the cerebellum and the spinal cord (Strakhova et al., 2009), the
intracerebroventricular administration of H4R agonist failed to
alter the spontaneous mobility and the exploratory activity in
mice (Galeotti et al., 2013). This indicates that the vestibular
neurons but not the central targets were influenced by the
blockade of the H4R (Wersinger et al., 2013). These evidences
also suggest that the vestibular lesions were the most likely
responsible for the behavior abnormalities that were observed in
this study.
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FIGURE 4 | Effects of the orexin receptor type 1 (OX1R) antagonist SB334867 on exploratory behavior in the open field after vestibular lesions induced
by arsanilate and IDPN in rats. Total distance traveled (A,B), body center-point moving duration (C,D), highly mobile duration (E,F) and immobile duration (G,H)
were analyzed; AVL, arsanilate-induced vestibular lesion; SHAM, sham control; IVL, IDPN-induced vestibular lesion; SAL, saline control; Veh, vehicle solution; SB,
SB334867. Data are represented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 compared with SHAM or SAL vehicle control group; #P < 0.05, ##P <
0.01 compared with AVL or IVL vehicle control group.
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Previous studies indicated that orexin expression in the LHA
neurons can be stimulated by homeostatic perturbations that
were induced by altered sleep andmetabolism, exposure to drugs,
or other noxious insults (Machaalani et al., 2013). Functional
studies have demonstrated that the vestibular system is involved
in regulating biological circadian, autonomic responses and
energy metabolism in the context of vestibular pathology and
balance disorder (Fuller et al., 2002). For example, the activation
of the vestibular system can disrupt energy homeostasis via
enhancing the thermolysis and suppressing the resting energy
expenditure during motion sickness in humans (Cheung et al.,
2011; Wang et al., 2016). Disrupted daily rhythms of the body
temperature and physical activity were observed in animals with
vestibular loss caused by genetic mutation or arsanilate injection
(Fuller et al., 2002; Martin et al., 2015). In the present study,
we revealed that the OXA expression in the hypothalamus was
increased in the arsanilate-treated animals at the time when the
vestibular deficit syndrome and locomotor hyperactivity were
fully produced. As for the orexin system also play important
roles in circadian regulation, energy homeostasis, and autonomic
responses (Boss and Roch, 2015), our results suggest that the
vestibular disorder-induced homeostatic disturbances might be
associated with alterations in orexin activity. However, whether
the vestibular system can directly regulate the activity of the
orexin system is not clarified in this study and needs further
investigations.
In the IDPN-treated animals, the orexin expression was
increased before the vestibular deficit syndrome was significantly
induced. It seems that IDPN may influence the orexin activity
through different mechanisms compared with arsanilate which
only induces damages restricted to the vestibular sensory organs
(Vignaux et al., 2012). One explanation may involve the direct
effects of IDPN on monoamines contents in the brain. IDPN
primarily affects the 5-hydroxytryptamine (5-HT) containing
neurons, leading to a widely decrease in the 5-HT and 5-
hydroxyindoleacetic acid levels in all of the brain regions
(Langlais et al., 1975; Wakata et al., 2000). IDPN also can
reduce dopamine and its metabolites’ levels through depressing
dopamine metabolic turnover (Wakata et al., 2000). The deceases
in monoamine levels are likely to stimulate the orexin system via
deactivation of the 5-HT1A and dopamine D2 receptor sites in the
LHA (Muraki et al., 2004; Bubser et al., 2005). Another possible
mechanism may involve oxidative stress induced by IDPN in
the brain through the excessive generation of the oxygen-derived
free radicals via the depletion of glutathione (Tariq et al., 2002;
Ahmad Khan et al., 2004; Stefanescu and Ciobica, 2012). Free
radical scavenger that inhibits the process of hydroxyl radical
formation is effective against the vestibular deficit syndrome
induced by IDPN (Nomoto, 2004). Recent studies showed that
OXA has anti-oxidant and anti-apoptotic effects against neuronal
damage (Esmaeili-Mahani et al., 2013). Therefore, we speculate
that the increase in orexin expression might be a result of IDPN-
induced oxidative stress in the central nervous system.
In the current study, the OX1R antagonist SB334867
significantly alleviated the vestibular deficit syndrome and
locomotor hyperactivity in the home cages in the AVL and IVL
animals. These results suggested that the elevated OXA activity
might play a role in vestibular loss-induced locomotor deficits
and hyperkinesia. Previous studies suggest that locomotor
hyperactivity and vestibular deficit syndrome might be due to
the altered dopaminergic activity via vestibular–basal ganglia
connection in vestibular-deficient animals (Stiles and Smith,
2015). It is noteworthy that the basal ganglia subregions such as
the striatum, the subthalamic nucleus and the substantia nigra
pars compacta are also densely innervated by the orexinergic
fibers and express the orexinergic receptors (Hu et al., 2015).
Microinjection of orexin into the substantia nigra pars compacta
apparently increased the movement time in rats (Kotz et al.,
2006). However, the orexin neurons also project widely to
the centers of the ascending activating system including the
laterodorsal tegmental, the pedunculopontine tegmental, the
basal forebrain, the locus coeruleus, the dorsal raphe and the
tuberomamillary nucleus (Sinton, 2011). Pharmacological and
optogenetic studies have demonstrated that these connections
not only participate in regulating sleep/wake transition, but
also play a role in modulating arousal and locomotor activity
(Hagan et al., 1999; Adamantidis et al., 2007). Furthermore, the
orexin system can also regulate the resting and active motor
thresholds via the connections with the motor cortex (Peyron
et al., 1998; Oliviero et al., 2005). Orexin knockout mice exhibited
a significant decrease in voluntary motor activity compared
with the wild type animals (Hara et al., 2001). These evidences
suggest that vestibular loss-induced spontaneous or voluntary
locomotor hyperactivity might involve multiple motor control
structures that receive the orexinergic innervations. Nevertheless,
the current study also revealed that SB334867 only attenuated
circling, retropulsion and abnormal head movements while the
contact inhibition of the righting reflex, the tail-hanging reflex
and the air-righting reflex still remained abnormal in the VL
animals. Functional and anatomical studies confirmed that the
vestibular nuclei receive the projections from the cortex, the
cerebellum and some brainstem structures in addition to the
vestibular nerve inputs (Cullen, 2012). Clinical investigations
in patients showed that the loss of vestibular-ocular reflexes
and vestibulo-spinal reflexes resulted in oscillopsia and gait
ataxia, respectively (Mamoto et al., 2002). In addition, bilateral
microinjection of SB334867 into the lateral vestibular nucleus did
not affect rat motor performance in either the horizontal balance
beam or the negative geotaxis test (Zhang et al., 2011). These
evidences suggest that the orexin systemmay not regulate balance
and postural control which involves the multimodal interactions
and multiple vestibular reflex pathways.
Our study also showed that the OX1R antagonist attenuated
vestibular loss-induced exploratory behavior in a new
environment. This result is in agreement with a previous
observation showing that activation of the orexin system
increased exploration and arousal in a novel environment in
rats. (Heydendael et al., 2014). Nevertheless, microinjection of
SB334867 into bilateral vestibular nucleus did not affect the
exploratory activity in an open field, indicating that orexin
regulates these behaviors via acting on other brain structures
(Zhang et al., 2011). In addition, it was reported that the
orexin neurons were activated by a fear-conditioned cue,
but not by restraint stress (Furlong et al., 2009). The orexin
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receptor blockade significantly reduced the cardiovascular and
exploratory responses induced by fear but not by cold exposure
(Furlong et al., 2009). These evidences strongly suggest that
orexin neurons can be activated by psychological stressors
but not by physical stressors. In the present study, in order to
minimize pain and physical stress that were induced by the
vestibular lesions, we set sham operation and saline control
groups in the AVL and IVL experiment, respectively, and used
antibiotics and analgesics after the intra-tympanic injection of
arsanilate. Given that the vestibular lesions in the acute phase
significantly induced hyperactivity but not led to hypoactivity
that is commonly seen in psychologically stressed animals, we
speculate that acute stress might not be the activator of the
orexin neurons. Interestingly, clinical investigations described
that patients with the vestibular disorders, such as migrainous
vertigo and Menière disease, have high rates of coexistence of
psychiatric disorders especially depression/anxiety (Yuan et al.,
2015). Vestibular stimuli exceeding the capacity to integrate
multimodal information, not only generates the typical motion
sickness-related physiological responses, but also contributes
to anxiety and fear under specific circumstances (Coelho and
Balaban, 2015). A recent study found that vestibular stimulation
relieved depression and anxiety and improved sleep quality and
autonomic functions in college students that were exposed to
the competitive environments in college (Kumar et al., 2016).
These results suggest that the vestibular system might play a role
in regulating motivated behaviors and psychological responses.
However, whether orexin is also involved in modulating
psychological responses in animals and humans with vestibular
dysfunction is still unclear and merits further investigation.
In summary, vestibular deficit syndrome and locomotor
hyperactivity were fully induced in rats that received the AVL
and IVL treatment. The AVL animals also exhibited increased
exploratory behavior in an open field. The H4R inhibitor
attenuated the vestibular deficit syndrome and eliminated
locomotor and exploratory hyperactivity in both AVL and
IVL animals, indicating that these behavior responses were
mainly induced by vestibular lesion. The novel findings of
the present study were that the AVL and IVL treatment
significantly increased orexin expression in the hypothalamus.
The OX1R inhibitor significantly attenuated the vestibular deficit
syndrome and locomotor hyperactivity in both AVL and IVL
animals, and decreased exploratory behavior in the AVL animals
compared with the vehicle controls. These results suggest that
the vestibular system may potentially regulate the activity of the
orexin system which might contribute to the acute locomotor
abnormalities that can be induced vestibular damage or
dysfunctions.
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